Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 72808 record(s)

Req # A-2019-000441

Any correspondence between Health Canada and any representative of Purdue Pharmaceutical in regards to any deceptive or manipulative marketing practices by the company in the sales of any of its products, in particular, of OyxContin by Purdue…

Organization: Health Canada

31 page(s)
April 2020

Req # A-2019-000958

All documents related to the natural health product licence submission, assessment, and decision for Ovomet.

Organization: Health Canada

174 page(s)
April 2020

Req # A-2019-001646

Adverse Reaction Report (AER) for HYDROCHLOROTHIAZIDE, IRBESARTAN. Report number: E2B_02372540.

Organization: Health Canada

7 page(s)
April 2020

Req # A-2019-001098

All correspondence records between any and/or all three Health Canada officials concerning the publication of the Draft Screening Assessment of Talc September 1, 2018 to December 31, 2018.

Organization: Health Canada

55 page(s)
April 2020

Req # A-2019-001606

All records between Health Canada and the Canadian Patient Safety Institute (CPSI) and/or Patients for Patient Safety Canada (PFPSC) on the results of the CPSI and PFPSC 2018 public survey related to the labelling of non-prescription health products…

Organization: Health Canada

20 page(s)
April 2020

Req # A-2019-001627

Health Canada reviewer's reports for the Fiasp (insulin aspart injection) New Drug Submission.

Organization: Health Canada

175 page(s)
April 2020

Req # A-2019-001634

On August 30, 2019 Health Canada was sent an application for approval of a Class 3 Cryotherapy device. Provide all possible details regarding the application and results.

Organization: Health Canada

13 page(s)
April 2020

Req # A-2019-001749

Copy of Natural Health Products Ingredients Database (NHPID) Issue Form submission and all the related records and reports used to substantiate the safety, efficacy and/or quality of the chemical substance Polylactic acid-glycolic acid copolymer as…

Organization: Health Canada

8 page(s)
April 2020

Req # A-2019-001653

Adverse Reaction Report (AER) for PSEUDOEPHEDRINE HYDROCHLORIDE. Report number: E2B_02601741.

Organization: Health Canada

11 page(s)
April 2020

Req # A-2019-001772

Advise whether the Abbreviated New Drug Submission (ANDS) for liraglutide accepted into review on August 2017 has received either: Notice of Deficiency (NOD); Notice of Non-Compliance (NON); NOD-Withdrawal (NOD-W) or NON-Withdrawal (NON-W).

Organization: Health Canada

5 page(s)
April 2020
Date modified: